metaPreg - Imipramine during pregnancy

Imipramine updated on 10-20-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.23 [0.17, 9.15]	68%	2 studies	31,381	17	not evaluable	ROB	-
Major congenital malformations	0.99 [0.14, 7.09]	47%	2 studies	30,830	14	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
4 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
4 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal disorders (as a whole)	2.41 [1.43, 4.06]	-	1 study	161,448	64	not evaluable	ROB	4.25 [2.21; .]
4 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Child/Infant death (> 28 days of life)	27.95 [1.72, 454.24]	-	1 study	130	64	not evaluable	ROB	55.41 [2.83; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study